Abstract
The protease inhibitors are potent antiretroviral drugs because the protease activity is absolutely essential for production of infectious viruses. The newest class of drugs is the fusion inhibitors that blocks virus entry into cells. Persistent virus production is facilitated further by sub-inhibitory drug levels in infected cells or by host immune failure. Therefore, pre-existing or newly produced drug resistant mutants can emerge that have a selective advantage under drug pressure. These escape mutants become dominant in the virus population and lead to viral rebound and therapy failure. This review provides knowledge for improvement of antiretroviral drug administration programmes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of HIV for Clinical and Scientific Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
